Pandian Jesu, Raghavan Vineetha, Manuprasad A, Shenoy Praveen Kumar, Nair Chandran K
Department of Clinical Hematology & Medical Oncology, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.
Support Care Cancer. 2020 Nov;28(11):5449-5454. doi: 10.1007/s00520-020-05379-z. Epub 2020 Mar 12.
A large number of AML patients present with infection at the time of initial presentation in Indian settings. There is lack of published data on the proportion of patients with infection at initial presentation and its impact on induction mortality.
A retrospective audit of patients with newly diagnosed AML more than 14 years of age, who underwent standard induction chemotherapy between the periods of January 2011 to December 2018, was done. Infection at presentation if any was documented. Induction mortality was defined as death happening within 28 days of starting induction chemotherapy.
Among a total of 315 cases of AML, 96 (30%) patients underwent induction chemotherapy with 7 + 3 regimen. Documented infection at baseline was present in 30 (31%) of patients. Another 10 patients had fever at the time of presentation but without any documented infection focus. Fifteen patients died within 4 weeks of induction amounting to induction mortality of 15.6%. Induction mortality was 28% among patients with infection at baseline compared with 7% without baseline infections (P = 0.01).
Around 40% of patients had fever at the time of presentation, and 31% had documented infections. Baseline infections led to increase in induction mortality. We would like to propose that infection at baseline is to be considered as one of the potential variables in the predictive scoring system for induction mortality in developing countries.
在印度,大量急性髓系白血病(AML)患者在初次就诊时就伴有感染。目前缺乏关于初次就诊时伴有感染的患者比例及其对诱导缓解期死亡率影响的公开数据。
对2011年1月至2018年12月期间接受标准诱导化疗的14岁以上新诊断AML患者进行回顾性审计。记录就诊时是否存在感染。诱导缓解期死亡率定义为开始诱导化疗后28天内死亡。
在总共315例AML病例中,96例(30%)患者接受了7+3方案的诱导化疗。30例(31%)患者在基线时有记录的感染。另外10例患者在就诊时有发热,但无任何记录的感染灶。15例患者在诱导缓解期4周内死亡,诱导缓解期死亡率为15.6%。基线时有感染的患者诱导缓解期死亡率为28%,而无基线感染的患者为7%(P=0.01)。
约40%的患者在就诊时有发热,31%有记录的感染。基线感染导致诱导缓解期死亡率增加。我们建议,在发展中国家,基线感染应被视为诱导缓解期死亡率预测评分系统中的潜在变量之一。